Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Anti-IL-6R: Phase IIb started

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Anti-IL-6R (ALX-0061) Business: Autoimmune Molecular target: Interleukin-6 (IL-6) receptor (CD126) Description: Nanobody …

    Published on 3/30/2015
  • AZP-531: Phase IIa started

    Alize Pharma, Lyon, France Product: AZP-531 Business: Endocrine/Metabolic Molecular target: Ghrelin Description: Unacylated ghrelin analog Indication: Treat Prader-Willi syndrome Endpoint: Safety; effects on fullness/…

    Published on 3/30/2015
  • CLS-TA: Phase II started

    Clearside Biomedical Inc., Alpharetta, Ga. Product: CLS-TA, CLS-1001 Business: Ophthalmic Molecular target: Glucocorticoid receptor (GCCR) Description: Triamcinolone acetonide delivered using the companys ocular …

    Published on 3/30/2015
  • DPX-Survivac: Phase II started

    Immunovaccine Inc. (TSX:IMV), Halifax, Nova Scotia Product: DPX-Survivac Business: Cancer Molecular target: Survivin (BIRC5) Description: Vaccine comprising survivin (BIRC5)-based peptide antigens formulated using …

    Published on 3/30/2015
  • Epi proColon: Clinical trial completed enrollment

    BioChain Institute Inc., Newark, Calif. Epigenomics AG (Xetra:ECX; OTCQX:EPGNY), Berlin, Germany Product: Epi proColon, Epi proColon 2.0 Business: Diagnostic Molecular target: Septin 9 (SEPT9) Description: Second-…

    Published on 3/30/2015
  • Fruquintinib: Completed Phase II enrollment

    Hutchison China MediTech Ltd. (LSE:HCM), Hong Kong, China Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Fruquintinib (HMPL-013) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) …

    Published on 3/30/2015
  • GCS-100: Phase IIb started

    La Jolla Pharmaceutical Co. (NASDAQ:LJPC), San Diego, Calif. Product: GCS-100 Business: Renal Molecular target: Galectin-3 (LGALS3) Description: Galectin-3 (LGALS3) inhibitor Indication: Treat stage 3b or 4 chronic …

    Published on 3/30/2015
  • Geodon ziprasidone: Phase III started

    RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Meiji Seika Pharma Co. Ltd., Tokyo, Japan Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Geodon ziprasidone (ME2112) Business: Neurology Molecular target: Serotonin (5-…

    Published on 3/30/2015
  • LJPC-501: Phase III started

    La Jolla Pharmaceutical Co. (NASDAQ:LJPC), San Diego, Calif. Product: LJPC-501 Business: Cardiovascular Molecular target: NA Description: Renin-angiotensin system peptide agonist Indication: Treat catecholamine-…

    Published on 3/30/2015
  • Onfi clobazam: Phase III started

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Product: Onfi clobazam Business: Neurology Molecular target: GABA A receptor Description: 1,5-benzodiazepine Indication: Adjunctive treatment of Dravet syndrome Endpoint: …

    Published on 3/30/2015
  • Retosiban: Phase III started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Retosiban (GSK221149) Business: Genitourinary Molecular target: Oxytocin receptor (OXTR) Description: Small molecule oxytocin receptor (OXTR) antagonist …

    Published on 3/30/2015
  • Rhopressa: Completed Phase III enrollment

    Aerie Pharmaceuticals Inc. (NASDAQ:AERI), Bedminster, N.J. Product: Rhopressa (AR-13324) Business: Ophthalmic Molecular target: Rho kinase; Norepinephrine transporter Description: Dual inhibitor of Rho kinase and the …

    Published on 3/30/2015
  • Scyllo-inositol: Completed Phase II enrollment

    Transition Therapeutics Inc. (TSX:TTH; NASDAQ:TTHI), Toronto, Ontario Product: Scyllo-inositol (AZD-103, ELND005) Business: Neurology Molecular target: Beta amyloid Description: Small molecule that disaggregates beta …

    Published on 3/30/2015
  • Sotagliflozin: Phase III started

    Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas Product: Sotagliflozin (LX4211 tablet) Business: Endocrine/Metabolic Molecular target: Sodium-glucose cotransporter 1 (SGLT1); Sodium-glucose …

    Published on 3/30/2015
  • TTFields: Phase II started

    Novocure Ltd., Isle of Jersey Product: TTFields Business: Cancer Molecular target: NA Description: Low intensity, intermediate frequency, alternating electric fields that disrupt mitosis and cytokinesis delivered via …

    Published on 3/30/2015
  • ZL-2102: Phase I started

    Zai Laboratory Inc., Shanghai, China Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: ZL-2102 Business: Pulmonary Molecular target: NA Description: Anti-inflammatory compound Indication: Treat chronic respiratory…

    Published on 3/30/2015
  • Zorblisa: Phase III started

    Scioderm LLC, Raleigh, N.C. Product: Zorblisa (SD-101) Business: Dermatology Molecular target: NA Description: Undisclosed topical cream Indication: Treat epidermolysis bullosa Endpoint: Proportion of patients achieving…

    Published on 3/30/2015
  • Algenpantucel-L: Phase III ongoing

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Product: Algenpantucel-L (HyperAcute Pancreas) Business: Cancer Molecular target: NA Description: Allogeneic cancer vaccine containing irradiated pancreatic tumor cells …

    Published on 3/10/2014
  • Alirocumab: Phase III ongoing

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 3/10/2014
  • ARC-520: Phase IIa started

    Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. Product: ARC-520 Business: Infectious Molecular target: NA Description: Short interfering RNAs targeting 2 regions of the HBV genome conjugated to N-…

    Published on 3/10/2014
  • BTI-320: Phase II start

    Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H. Product: BTI-320 (formerly PAZ320) Business: Endocrine/Metabolic Molecular target: NA Description: Chewable polysaccharide that blocks the action of carbohydrate-…

    Published on 3/10/2014
  • EBI-005: Phase II started

    Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Product: EBI-005 Business: Inflammation Molecular target: Interleukin-1 (IL-1) Description: IL-1 receptor antagonist Indication: Treat allergic conjunctivitis …

    Published on 3/10/2014
  • Emixustat: Completed Phase IIb/III enrollment

    Acucela Inc. (Tokyo:4589), Seattle, Wash. Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Product: Emixustat (formerly ACU-4429) Business: Ophthalmic Molecular target: NA Description: Non-retinoid visual cycle modulator …

    Published on 3/10/2014
  • Emricasan: Phase II started

    Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), San Diego, Calif. Product: Emricasan (PF-3491390, IDN-6556, PF-03491390) Business: Hepatic Molecular target: Caspases Description: Pan-caspase inhibitor Indication: Treat non-…

    Published on 3/10/2014
  • Glassia: Phase II/III started

    Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA), Ness Ziona, Israel Product: Glassia (IV Alpha-1 Antitrypsin (AAT)) Business: Endocrine/Metabolic Molecular target: Elastase Description: IV formulation of human plasma derived …

    Published on 3/10/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993